SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ:DXCM), the leader in continuous glucose monitoring for people with diabetes, announced today the U.S. Centers for Medicare & Medicaid Services (CMS) is ...

The FDA has approved San Diego, California-based Dexcom for a Bluetooth-enabled continuous glucose monitor (CGM), called the G5 Mobile CGM system. Correction: A previous version of this article ...

Share price of DexCom, Inc.DXCM jumped 4.8% on Aug 25, following the FDA approval of the DexCom G5 Mobile Continuous Glucose Monitoring (CGM) System. The fully portable product is the first and ...

This approval marks the Company’s fifth new insulin pump launch in only 5 years and the second featuring Dexcom technology. It is the only available pump that conveniently displays a user’s insulin ...

As expected, an FDA panel voted in favor of giving Dexcom’s ($DXCM) G5 continuous glucose monitor a nonadjunctive indication that would allow it to be used in place ...

Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with ...

A literature search was carried out for this briefing in accordance with NICE's interim process and methods statement for the production of medtech innovation briefings. This briefing includes the ...